Announced details
Endoscopic administration; methods of administering oncolytic adenoviruses without limiting the cancer type; expansion of OBP-301 indications; application to OBP-702
Removal of the limitation on administration time expanded the patent's coverage and applications.
Patent No. 7674738 (registered in 2025); the divisional application has received a decision to grant a patent. The patent term runs through May 2040.
The impact on the Company's financial results for the fiscal year ending December 2026 is expected to be minor.
The company does not address Contract Value / Offering price.
| Item | Details |
|---|---|
| Names of Products / Services Covered | OBP-301, OBP-702, Method of Endoscopically Administering Oncolytic Adenoviruses |
| Applicable area | Endoscopic administration; methods of administering oncolytic adenoviruses without limiting the cancer type; expansion of OBP-301 indications; application to OBP-702 |
| Registration number and expiry date | Patent No. 7674738 (registered in 2025); the divisional application has received a decision to grant a patent. The patent term runs through May 2040. |
| Quantitative Effects | Removal of the limitation on administration time expanded the patent's coverage and applications. |
| Impact on Business Performance | The impact on the Company's financial results for the fiscal year ending December 2026 is expected to be minor. |
Items this document does not state (13)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Removing the limitation on administration time expanded the patent's coverage and broadened its applications.